Bevacizumab Pipeline Development Activities and Emerging Therapies
“Bevacizumab Biosimilar Insight, 2020,” report by Delveinsight provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape.
Bevacizumab Biosimilar Insight report analyses the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Bevacizumab Biosimilar therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Bevacizumab Biosimilar pipeline products in this space.
Bevacizumab Biosimilars Drugs segment of the Bevacizumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bevacizumab Biosimilars Emerging Drugs
The report provides an analysis of the Bevacizumab Biosimilars Emerging Drugs. Some of the key Emerging Drugs drugs covered in the report include:
- HD204: Prestige BioPharma - Prestige BioPharma is developing HD204 for the treatment of several Solid Tumors. In 2019, Prestige BioPharma announced positive results from a phase I clinical trial (SAMSON-I) evaluating the pharmacokinetics (PK), safety and immunogenicity of biosimilar candidate HD204 to Avastin (bevacizumab).
- GB 222: Genor Biopharma - Genor Biopharma is developing GB 222 for the treatment of Non-small cell lung cancer. The drug is currently in phase III stage of development.
Further products details are provided in the report, for more information, visit: Bevacizumab Biosimilars Emerging Drugs
Bevacizumab Pipeline Development Activities
Bevacizumab Biosimilars Insight report provides an analysis of different therapeutic candidates in marketed, phase III, II, I and preclinical stages. It also analyses Bevacizumab biosimilars drugs key players involved in developing key drugs. The pipeline development activities of the report cover the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging bevacizumab biosimilar drugs.
Bevacizumab Biosimilars Insight Report Insights
- Bevacizumab Biosimilar Pipeline Analysis
- Therapeutic Assessment
- Sales Assessment
- Unmet Needs
- Impact of Drugs
Bevacizumab Biosimilars Insight Report Assessment
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Need
Some of the key Bevacizumab Biosimilars companies covered in the report include:
BioIntegrator, Mycenax Biotech, Biocad, Daiichi Sankyo/ Amgen, Kashiv BioSciences, Harvest Moon Pharmaceuticals, Coherus BioSciences, Celltrion, Centus Biotherapeutics Limited, Shanghai Henlius Biotech, Innovent Biologics, mAbxience S.A, Amgen/ Allergan, Outlook Therapeutics, Pfizer, R-Pharm, Samsung Bioepis, Zhejiang Teruisi Pharmaceutical, Tanvex Biopharma, Pfizer, Zydus Cadila, Reliance Life Sciences, Laboratorio Elea, Biocon/Mylan, Bio-Thera Solutions, BioXpress Therapeutics, Boehringer Ingelheim, Zydus Cadila, Dr Reddy’s, mAbxience, Genor Biopharma, Gene Techno Science, and many others.
For more details, visit: Bevacizumab Pipeline Development Activities and Emerging Therapies